InsidersTradesSigma
Track the Vicarious Surgical Inc. stock price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Vicarious Surgical Inc. has published 292 reports. The latest transaction was filed on 24 February 2026 (Cession). Among the most active insiders: Sachs Adam David. Every trade is accessible without an account.
292
Insider Decl.
n/a
Thresholds
€15m
23 ops.
Buy Volume
€2m
166 ops.
Sell Volume
37Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 24 February 2026
Declarations292 total
942 shares@ US$2.08780.3% of flowClass A Common StockSEC:0001213900-26-019944:0
754 shares@ US$2.08410.3% of flowClass A Common StockSEC:0001213900-26-019943:0
463 shares@ US$2.9520.2% of flowClass A Common StockSEC:0001213900-25-118410:0
239 shares@ US$2.970.1% of flowClass A Common StockSEC:0001213900-25-118409:0
653 shares@ US$2.7440.3% of flowClass A Common StockSEC:0001213900-25-113763:0
816 shares@ US$2.7150.4% of flowClass A Common StockSEC:0001213900-25-113762:0
463 shares@ US$5.75640.4% of flowClass A Common StockSEC:0001213900-25-084550:0
239 shares@ US$5.71950.3% of flowClass A Common StockSEC:0001213900-25-084549:0
2,753 shares@ US$6.696596.5% of flowClass A Common StockSEC:0001213900-25-081179:0
653 shares@ US$6.04220.8% of flowClass A Common StockSEC:0001213900-25-079495:0
817 shares@ US$6.03120.8% of flowClass A Common StockSEC:0001213900-25-079494:0
100 shares@ US$6.68100.0% of flowClass A Common StockSEC:0001213900-25-079492:0
279 shares@ US$7.79960.4% of flowClass A Common StockSEC:0001213900-25-057361:0
223 shares@ US$7.81450.3% of flowClass A Common StockSEC:0001213900-25-057359:0
239 shares@ US$7.25090.3% of flowClass A Common StockSEC:0001213900-25-051100:0
463 shares@ US$7.21930.6% of flowClass A Common StockSEC:0001213900-25-051099:0
653 shares@ US$7.52240.8% of flowClass A Common StockSEC:0001213900-25-046364:0
817 shares@ US$7.52770.9% of flowClass A Common StockSEC:0001213900-25-046363:0
129 shares@ US$7.97070.2% of flowClass A Common StockSEC:0001013762-25-001639:0
161 shares@ US$7.91960.2% of flowClass A Common StockSEC:0001013762-25-001641:0
276 shares@ US$10.25250.5% of flowClass A Common StockSEC:0001213900-25-020276:0
535 shares@ US$10.27910.9% of flowClass A Common StockSEC:0001213900-25-020272:0
264 shares@ US$10.277117.7% of flowClass A Common StockSEC:0001213900-25-020275:0
943 shares@ US$14.53322.2% of flowClass A Common StockSEC:0001213900-25-016007:0
754 shares@ US$14.53052.0% of flowClass A Common StockSEC:0001213900-25-016006:0
25 of 292 declarations
关于 Vicarious Surgical Inc.
Vicarious Surgical Inc. 是一家总部位于美国马萨诸塞州沃尔瑟姆的美国医疗机器人公司，通过股票代码 RBOTW 在美国市场（特别是 NYSE/NASDAQ 体系）上市。该公司成立于 2014 年，正在开发一个专注于微创手术的下一代手术机器人平台。从股票研究的角度来看，Vicarious Surgical 最好被视为一家颠覆性的早期医疗技术开发商，试图挑战现有机器人手术系统的经济性和可用性。其战略目标是扩大机器人手术的可及性，同时提高手术效率，并最终帮助降低医疗成本。([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai)) 该公司的核心业务是专有手术机器人的设计和推进，而非成熟的、规模化的商业特许经营。这对投资者很重要：公司的发展更多地取决于产品开发里程碑、临床验证、监管进展、资本纪律和最终的医院采用，而不是当前的销售额。换句话说，Vicarious Surgical 具有早期商业化或商业化前医疗保健机器人公司的典型风险/回报特征。其上行空间取决于证明其系统能够在实际操作环境中提供差异化的临床和经济价值。([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai)) 在竞争方面，该公司在一个由规模更大、资本更雄厚的参与者主导的市场中运营，其中最著名的是 Intuitive Surgical。Vicarious Surgical 试图通过不同的机器人架构和以更好的灵活性、改进的可视化、增强的外科医生人体工程学以及潜在的更低总手术成本为核心的价值主张脱颖而出。这种颠覆性的定位很有趣，但也意味着执行风险很高。市场将希望看到工程准备就绪、可重复的性能、安全性以及可信的商业化途径的证据，然后才会给予持久的溢价估值。([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai)) 从地理上看，该业务主要以美国为中心，其总部和主要公司所在地位于马萨诸塞州。公开披露和投资者沟通表明，该公司仍专注于美国的核心运营和资本市场拓展。该公司的投资者关系材料、收益发布和会议参与也表明，其叙述仍以开发和融资为基础，而非广泛的国际销售。这对于处于生命周期这一阶段的机器人平台公司来说是典型的。([investor.vicarioussurgical.com](https://investor.vicarioussurgical.com/overview/?utm_source=openai)) 截至 2025 年和 2026 年的最新更新强调了现金消耗管理、季度财务业绩以及与投资界的持续互动。这些披露很重要，因为它们构成了公司近期优先事项的框架：保持流动性、推进平台以及为未来商业化保持选择权。内幕人士 Form 4 活动在市场上也可见，这通常会引起试图衡量管理层情绪的小盘股投资者的关注。总的来说，RBOTW 仍然是一个投机性的医疗保健机器人名称，其表现与技术执行、融资需求以及公司将有前景的概念转化为商业上可行的手术系统的能力息息相关。([stocktitan.net](https://www.stocktitan.net/sec-filings/RBOT/form-4-vicarious-surgical-inc-insider-trading-activity-bd58b7e8dadf.html?utm_source=openai))
